HOW DOES FINGOLIMOD (GILENYA®) FIT IN THE TREATMENT ALGORITHM FOR HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS?

HOW DOES FINGOLIMOD (GILENYA®) FIT IN THE TREATMENT ALGORITHM FOR HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS?

Multiple sclerosis (MS) is a neurological disorder characterised by inflammatory demyelination and neurodegeneration in the central nervous system (CNS). Until recently, disease modifying treatment was based on agents requiring parenteral delivery, thus limiting long-term compliance. Basic treatment...

Full description

Bibliographic Details
Main Authors: Franz eFazekas, Ovidiu eBajenaru, Thomas eBerger, Tanja eHojs Fabjan, Alenka eHorvat Ledinek, Gábor eJakab, Samuel eKomoly, Tetiana eKobys, Jörg eKraus, Egon eKurča, Theodore eKyriakides, Lubomír eLisý, Ivan eMilanov, Sergii eMoskovko, Tetyana eNehrych, Panayiotis ePanayiotou, Sasa eSega Jazbec, Larysa eSokolova, Radomir eTalab, Latchezar eTraykov, Peter eTurčáni, Karl eVass, Norbert eVella, Nataliya eVoloshyna, Eva eHavrdova
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-05-01
Series:Frontiers in Neurology
Subjects:
Multiple Sclerosis
Treatment
algorithm
fingolimod
expert oppininion
Online Access:http://journal.frontiersin.org/Journal/10.3389/fneur.2013.00010/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fneur.2013.00010/full

Similar Items